PA
PRCT icon

Pinnacle Associates’s Procept Biorobotics PRCT Stock Holding History

Pinnacle Associates’s Portfolio PRCT Stock Details PRCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.48M Sell
109,976
-4,649
-4% -$116K 0.03% 384
2026
Q1 		$2.87M Sell
114,625
-8,569
-7% -$241K 0.04% 342
2025
Q4 		$3.88M Buy
+123,194
New +$4.09M 0.05% 279

Other funds holding PRCT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $99.8B AUM 45.22% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CC
Chicago Capital Chicago, Illinois $4.15B AUM 31.09% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Pinnacle Associates's PRCT Position: Q2 2026 in Review

Pinnacle Associates reduced its Procept Biorobotics (PRCT) stake by 4.1% in Q2 2026, selling an estimated $116K and leaving 109,976 shares worth $2.48M. The position accounts for 0.03% of the portfolio, ranked #384.

Pinnacle Associates first reported a position in PRCT in Q4 2025 and has held it in 3 quarters since. The position peaked at $3.88M in Q4 2025. 254 funds tracked by Wall St. Rank hold PRCT as of Q2 2026.

  • Pinnacle Associates held 109,976 shares of Procept Biorobotics worth $2.48M as of Q2 2026.
  • Pinnacle Associates sold 4,649 Procept Biorobotics shares in Q2 2026, an estimated $116K.
  • Procept Biorobotics made up 0.03% of Pinnacle Associates's portfolio in Q2 2026, its #384 holding.
  • Pinnacle Associates first reported a position in Procept Biorobotics in Q4 2025 and has held it in 3 quarters since.
  • Pinnacle Associates's Procept Biorobotics position peaked at $3.88M in Q4 2025.
  • 254 funds tracked by Wall St. Rank held Procept Biorobotics as of Q2 2026.

Based on Pinnacle Associates's 13F filing for Q2 2026, filed 3 Aug 2026.